LIFEVANTAGE CORP (LFVN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
46/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinLFVN / S&P 45.37% / 15.20% |
LoseLFVN / S&P -20.10% / 15.00% |
LoseLFVN / S&P -45.95% / 50.40% |
| 2026-Q10/3 |
LoseLFVN / S&P -29.18% / -4.33% |
LoseLFVN / S&P -12.15% / 11.30% |
LoseLFVN / S&P -34.78% / 27.70% |
| 2025-Q40/3 |
LoseLFVN / S&P -36.27% / 2.65% |
LoseLFVN / S&P -0.99% / 9.00% |
LoseLFVN / S&P 7.14% / 13.40% |
| 2025-Q32/3 |
LoseLFVN / S&P -25.33% / 8.12% |
WinLFVN / S&P 16.77% / 4.61% |
WinLFVN / S&P 140.63% / 13.45% |
| 2025-Q22/3 |
LoseLFVN / S&P -9.97% / 10.94% |
WinLFVN / S&P 14.17% / 4.83% |
WinLFVN / S&P 221.74% / 10.63% |
| 2025-Q12/3 |
LoseLFVN / S&P -16.63% / -4.27% |
WinLFVN / S&P 8.22% / 4.98% |
WinLFVN / S&P 146.43% / 10.57% |
| 2024-Q42/3 |
WinLFVN / S&P 45.51% / 2.41% |
LoseLFVN / S&P 0.57% / 5.25% |
WinLFVN / S&P 143.48% / 6.15% |
| 2024-Q32/3 |
WinLFVN / S&P 88.94% / 5.89% |
LoseLFVN / S&P -7.97% / 5.89% |
WinLFVN / S&P 60.00% / 6.11% |
| 2024-Q22/3 |
WinLFVN / S&P 6.68% / 4.28% |
LoseLFVN / S&P -6.20% / 5.38% |
WinLFVN / S&P 15.00% / 5.12% |
| 2024-Q10/3 |
LoseLFVN / S&P 1.34% / 10.56% |
LoseLFVN / S&P -2.22% / 5.71% |
LoseLFVN / S&P -660.00% / 5.59% |
| 2023-Q40/3 |
LoseLFVN / S&P -6.46% / 11.69% |
LoseLFVN / S&P 2.21% / 6.81% |
LoseLFVN / S&P -675.00% / 7.78% |
| 2023-Q32/3 |
WinLFVN / S&P 57.46% / -3.27% |
LoseLFVN / S&P 3.94% / 7.52% |
WinLFVN / S&P 300.00% / -5.03% |
| 2023-Q21/3 |
WinLFVN / S&P 22.10% / 8.74% |
LoseLFVN / S&P 3.41% / 9.50% |
LoseLFVN / S&P -20.00% / -8.57% |
| 2023-Q10/3 |
LoseLFVN / S&P -2.74% / 7.50% |
LoseLFVN / S&P -0.04% / 10.77% |
LoseLFVN / S&P -107.14% / -15.69% |
| 2022-Q40/3 |
LoseLFVN / S&P -0.02% / 7.56% |
LoseLFVN / S&P -2.54% / 11.88% |
LoseLFVN / S&P -105.48% / -17.99% |
| 2022-Q30/3 |
LoseLFVN / S&P -13.14% / -4.88% |
LoseLFVN / S&P -6.25% / 13.47% |
LoseLFVN / S&P -94.90% / -1.41% |
| 2022-Q21/3 |
WinLFVN / S&P -7.93% / -16.10% |
LoseLFVN / S&P -6.28% / 13.71% |
LoseLFVN / S&P -72.22% / 11.04% |
| 2022-Q10/3 |
LoseLFVN / S&P -24.68% / -4.60% |
LoseLFVN / S&P -6.49% / 15.97% |
LoseLFVN / S&P -13.58% / 42.23% |
| 2021-Q40/3 |
LoseLFVN / S&P -6.65% / 11.03% |
LoseLFVN / S&P -7.64% / 15.00% |
LoseLFVN / S&P -8.75% / 96.40% |
| 2021-Q30/3 |
LoseLFVN / S&P -7.89% / 0.58% |
LoseLFVN / S&P -5.59% / 10.77% |
LoseLFVN / S&P 16.67% / 69.42% |
| 2021-Q20/3 |
LoseLFVN / S&P -21.39% / 8.55% |
LoseLFVN / S&P -5.47% / 6.58% |
LoseLFVN / S&P 13.92% / 51.81% |
| 2021-Q10/3 |
LoseLFVN / S&P 0.32% / 6.17% |
LoseLFVN / S&P -2.15% / -1.06% |
LoseLFVN / S&P 2.53% / 7.39% |
| 2020-Q42/3 |
LoseLFVN / S&P -22.78% / 12.15% |
WinLFVN / S&P -0.16% / -3.72% |
WinLFVN / S&P 0.00% / -33.42% |
| 2020-Q32/3 |
LoseLFVN / S&P -10.72% / 8.93% |
WinLFVN / S&P 2.18% / -2.04% |
WinLFVN / S&P 50.00% / -27.10% |
| 2020-Q23/3 |
WinLFVN / S&P 31.26% / 20.54% |
WinLFVN / S&P 3.08% / -0.46% |
WinLFVN / S&P 58.00% / -27.11% |
| 2020-Q11/3 |
LoseLFVN / S&P -34.02% / -19.60% |
LoseLFVN / S&P 2.63% / 3.47% |
WinLFVN / S&P 75.56% / -14.75% |
| 2019-Q42/3 |
WinLFVN / S&P 13.94% / 9.07% |
LoseLFVN / S&P 5.17% / 5.36% |
WinLFVN / S&P 77.78% / 2.99% |
| 2019-Q33/3 |
WinLFVN / S&P 5.55% / 1.70% |
WinLFVN / S&P 8.06% / 5.02% |
WinLFVN / S&P 36.59% / 0.21% |
| 2019-Q22/3 |
LoseLFVN / S&P -9.17% / 4.30% |
WinLFVN / S&P 11.20% / 6.64% |
WinLFVN / S&P 21.95% / 8.65% |
| 2019-Q12/3 |
LoseLFVN / S&P 8.34% / 13.65% |
WinLFVN / S&P 12.02% / 8.12% |
WinLFVN / S&P 125.00% / 14.29% |
| 2018-Q43/3 |
WinLFVN / S&P 20.02% / -13.52% |
WinLFVN / S&P 12.41% / 9.05% |
WinLFVN / S&P 462.50% / 18.23% |
| 2018-Q32/3 |
WinLFVN / S&P 72.53% / 7.71% |
LoseLFVN / S&P 8.24% / 10.21% |
WinLFVN / S&P 412.50% / 19.06% |
| 2018-Q22/3 |
WinLFVN / S&P 76.45% / 3.43% |
LoseLFVN / S&P 1.86% / 9.03% |
WinLFVN / S&P 310.00% / 14.46% |
| 2018-Q10/3 |
LoseLFVN / S&P -24.16% / -0.76% |
LoseLFVN / S&P -1.02% / 7.68% |
LoseLFVN / S&P -23.08% / 12.46% |
| 2017-Q41/3 |
WinLFVN / S&P 12.80% / 6.64% |
LoseLFVN / S&P -8.81% / 7.03% |
LoseLFVN / S&P -75.76% / 13.82% |
| 2017-Q30/3 |
LoseLFVN / S&P -2.54% / 4.48% |
LoseLFVN / S&P -10.35% / 5.68% |
LoseLFVN / S&P -80.95% / 17.57% |
| 2017-Q20/3 |
LoseLFVN / S&P -19.37% / 3.09% |
LoseLFVN / S&P -3.41% / 4.83% |
LoseLFVN / S&P -76.19% / 17.74% |
| 2017-Q10/3 |
LoseLFVN / S&P -34.11% / 6.07% |
LoseLFVN / S&P 1.55% / 3.67% |
LoseLFVN / S&P -10.34% / 13.32% |
| 2016-Q42/3 |
LoseLFVN / S&P -13.85% / 3.82% |
WinLFVN / S&P 13.43% / 2.09% |
WinLFVN / S&P 26.92% / 7.05% |
| 2016-Q32/3 |
LoseLFVN / S&P -30.44% / 3.85% |
WinLFVN / S&P 17.40% / 0.20% |
WinLFVN / S&P 68.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | LFVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -49.45% | 20.78% |
| Annualized return | -49.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | LFVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -2.49% | 83.14% |
| Annualized return | -0.50% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | LFVN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -41.04% | 319.30% |
| Annualized return | -5.15% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |